Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2576207 | 0.95 | TP53 (0.40) | MAPTCYP1A2POLBHPGDHTT | |
| SCHEMBL10902327 | 0.94 | MAPT (0.43) | MAPTCYP1A2POLBHPGDHTT | |
| SCHEMBL10471196 | 0.93 | TP53 (0.43) | MAPTCYP1A2HTTTP53PKM | |
| SCHEMBL10450411 | 0.93 | TP53 (0.43) | MAPTCYP1A2HTTTP53PKM | |
| SCHEMBL5478105 | 0.93 | TP53 (0.43) | MAPTCYP1A2HTTTP53PKM | |
| SCHEMBL7876219 | 0.89 | ARG1 (0.36) | MAPTLMNATLR4KMT2AARG1 | |
| SCHEMBL8774101 | 0.81 | MAPT (0.39) | MAPTCYP1A2POLBHPGDHTT | |
| SCHEMBL28319003 | 0.81 | CYP1A2 (0.47) | MAPTCYP1A2POLBHPGDHTT | |
| SCHEMBL11310025 | 0.81 | POLB (0.39) | POLBHPGDARG1ARG2ALDH1A1 | |
| SCHEMBL1080926 | 0.80 | FFAR3 (0.46) | MAPTCYP1A2POLBHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351587-B2 | Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-07-16 | — | — | US | disclosed |
| US-20110195942-A1 | METHOD OF MAKING AND USING 7ALPHA, 11BETA-DIMETHYL-17BETA-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN | 2011-08-11 | — | — | US | disclosed |
| EP-1873228-B1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL, OPTICAL ELEMENT, AND OPTICAL HEAD DEVICE | ASAHI GLASS CO LTD (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-7534370-B2 | Polymerizable liquid crystal composition, optical anisotropic material, optical element and optical head device | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20090023695-A1 | METHOD OF MAKING AND USING 7alpha,11beta-DIMETHYL-17beta-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH | 2009-01-22 | — | — | US | disclosed |
| US-20080048149-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL, OPTICAL ELEMENT AND OPTICAL HEAD DEVICE | ASAHI GLASS COMPANY, LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1873228-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL, OPTICAL ELEMENT, AND OPTICAL HEAD DEVICE | Asahi Glass Company, Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-7196074-B2 | Methods of making, using and pharmaceutical formulations comprising 7α, 11β-dimethyl-17β-hydroxyestra-4, 14-dien-3-one and 17 esters thereof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1272196-B1 | METHODS OF MAKING THE 4-N-BUTYLCYCLOHEXANOIC AND THE UNDECANOIC ACID ESTERS OF (7 ALPHA,11 BETA)-DIMETHYL-17 BETA-HYDROXY-4-ESTREN-3-ONE AND THEIR MEDICAL USE | US GOV HEALTH & HUMAN SERV (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1379253-B1 | METHODS OF MAKING AND PHARMACEUTICAL FORMULATIONS COMPRISING 7ALPHA,11BETA-DIMETHYL-17BETA-HYDROXYESTRA-4, 14-DIEN-3-ONE AND 17 ESTERS THEREOF | US GOV HEALTH & HUMAN SERV (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050130944-A1 | Method of making and using 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate | GOVERNMENT OF THE USA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-06-16 | — | — | US | disclosed |
| US-20030130243-A1 | Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof and 17 esters of 7alpha-methyl-17beta-hydroxyestra-4,14-dien-3-one | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, | 2003-07-10 | — | — | US | disclosed |
| US-20030069215-A1 | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, | 2003-04-10 | — | — | US | disclosed |
| US-6174573-B1 | 3,4'-(HALO OR HALOGEN),4-((CYCLO)ALK(OXY)CARBONYLOXY)-DIPHENYLACETYLENE COMPOUNDS WHICH INCREASE THE N-I POINT (NEMATIC ANISOTROPY PHASE TRANSITION TEMPERATURE), AND THE DOUBLE REFRACTIVE INDEX | CITIZEN WATCH CO., LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-5972244-A | INCREASE THE N-I POINT, DECREASE VISCOSITY, AND INCREASE DOUBLE REFRACTIVE INDEX OF A LIQUID CRYSTAL COMPOSITION WITHOUT AFFECTING THRESHOLD VOLTAGE | CITIZEN WATCH CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| US-5348677-A | Electro-optical liquid crystal display element | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-09-20 | — | — | US | disclosed |
| US-5196140-A | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-03-23 | — | — | US | disclosed |
| US-4948790-A | Long-acting androgenic compounds and pharmaceutical compositions thereof | ARCHER SYDNEY (US) | 1990-08-14 | — | — | US | disclosed |
| US-4626375-A | Liquid crystalline substances | VEB WERK FUER FERNSEHELEKTRONIK (DD) | 1986-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023695-A1 | METHOD OF MAKING AND USING 7alpha,11beta-DIMETHYL-17beta-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | HSD17B11, HSD17B13, HSD3B1 | MAPT 4310/4885CYP1A2 134/4885POLB 1313/4885 |
| US-20030130243-A1 | Methods of making, using and pharmaceutical formulations comprising 7alpha, 11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof and 17 esters of 7alpha-methyl-17beta-hydroxyestra-4,14-dien-3-one | HSD17B11, CYP19A1, HSD17B7 | MAPT 4718/4885CYP1A2 95/4885POLB 1556/4885 |
| US-20110195942-A1 | METHOD OF MAKING AND USING 7ALPHA, 11BETA-DIMETHYL-17BETA-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE | HSD17B11, HSD17B13, HSD3B1 | MAPT 4310/4885CYP1A2 134/4885POLB 1313/4885 |
| US-20050130944-A1 | Method of making and using 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate | HSD17B11, HSD17B13, HSD3B1 | MAPT 3648/4885CYP1A2 106/4885POLB 1513/4885 |
| US-10351587-B2 | Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate | HSD17B11, HSD17B13, CYP19A1 | MAPT 3820/4885CYP1A2 155/4885POLB 1830/4885 |
| US-20030069215-A1 | Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate | HSD17B11, CYP19A1, SHBG | MAPT 3964/4885CYP1A2 131/4885POLB 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.